Form D · Biotechnology
Regenovation, Inc.
New York, NY · CIK 0001683329
Offering snapshot reported Sep 8, 2016 · SEC filing
- Reported sold
- $1.38M Offering amount: $4M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Aug 5, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 8, 2016 | Initial | $1,375,500 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-270254
convertible debt
Source: Form D, filed Sep 8, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Phyllis Bellin | Executive |
| Isaac Blech | Director |
| Brady Dougan | Director |
| Jay Kranzler | Director, Executive |
| Andrew L. Pearlman | Director |
| Jessica Swartz | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1271 Avenue Of The Americas 16 Th Floor
New York, NY, 10020
New York, NY, 10020